GM-CSF Knockout CAR-T Cells for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chimeric antigen receptor T cell (CART) therapies for cancer, such as CD19-directed CART cells, are limited by toxicities like cytokine release syndrome (CRS) and neurotoxicity, and have only 40% durable remissions in lymphoma and 50-60% in acute leukemia, due to elevated GM-CSF levels.
Innovation Solution
A method involving a nucleic acid construct with a guide RNA complementary to GM-CSF mRNA, a Cas nuclease, and a chimeric antigen receptor is introduced into T cells to reduce GM-CSF expression, using CRISPR/Cas9 technology, specifically targeting exon 3 of the GM-CSF gene, resulting in GM-CSF knockout (KO) CART cells that maintain antitumor activity without CRS and neurotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CART cells are administered to treat cancer, then antitumor activity is improved, but cytokine release syndrome and neurotoxicity occur due to elevated GM-CSF levels
Solution Approach 1:
The patent extracts and removes the harmful GM-CSF component from the CART cell system by introducing a nucleic acid construct that knocks out GM-CSF expression. This selectively eliminates the harmful factor (GM-CSF) while preserving the beneficial antitumor activity of the CART cells through the retained CAR signaling domains.
Solution Approach 2:
The patent changes the expression parameter of GM-CSF from elevated to reduced/eliminated levels by modifying the nucleic acid sequence in the CART cell. This parameter change (GM-CSF expression level) directly resolves the contradiction by removing the cause of toxicity while maintaining therapeutic function.
2Reliability
If standard CART cell therapy is used, then cancer treatment efficacy is achieved, but durable remission rates are limited to 40-60%
Solution Approach 1:
The patent changes the GM-CSF expression parameter in CART cells to improve persistence and durability of the therapy. By reducing GM-CSF levels, the modified CART cells achieve enhanced long-term survival and persistence in the patient, thereby extending the duration of therapeutic action and improving durable remission rates.
3Object-affected harmful factors
If GM-CSF expression is reduced in CART cells, then toxicity is decreased, but antitumor activity must be maintained
Solution Approach 1:
The patent selectively extracts only the harmful GM-CSF function from the CART cell while preserving all essential antitumor functions. The nucleic acid construct is designed to knock out specifically the GM-CSF coding sequence, leaving intact the CAR antigen recognition domains and other cytotoxic machinery needed for antitumor activity.
Solution Approach 2:
The patent converts the harmful effect of GM-CSF elevation into a benefit by using the knowledge of GM-CSF's role in toxicity to deliberately eliminate it. The harmful GM-CSF expression is transformed into a targeted knockout, converting the source of harm into a therapeutic improvement while maintaining or enhancing overall antitumor efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
GM-CSF KO CART cells demonstrate enhanced antitumor activity, reduced GM-CSF production, and improved therapeutic window with durable disease control in leukemia models, while avoiding CRS and neurotoxicity, indicating a safer and more effective CART cell therapy.
Implementation Method 1
A method involving a nucleic acid construct with a guide RNA complementary to GM-CSF mRNA, a Cas nuclease, and a chimeric antigen receptor is introduced into T cells to reduce GM-CSF expression, using CRISPR/Cas9 technology, specifically targeting exon 3 of the GM-CSF gene
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
This document provides methods and materials involved in treating cancer. For example, chimeric antigen receptor T cells having reduced levels of GM-CSF are provided. Also provided as methods for making and using chimeric antigen receptor T cells having reduced levels of GM-CSF.